Ascelia Pharma AB
STO:ACE

Watchlist Manager
Ascelia Pharma AB Logo
Ascelia Pharma AB
STO:ACE
Watchlist
Price: 4.825 SEK -3.31% Market Closed
Market Cap: 559.8m SEK

EV/EBIT
Enterprise Value to EBIT

-7.1
Current
-8.8
Median
5
Industry
Higher than median
Lower than industry value

Enterprise Value to EBIT (EV/EBIT) ratio is a valuation multiple that compares the value of a company, debt included, to the company’s earnings before interest and taxes (EBIT). Considered one of the most frequently used multiples for comparisons among companies, the EV/EBIT multiple relies on operating income as the core driver of valuation.

EV/EBIT
-7.1
=
Enterprise Value
503.2m SEK
/
EBIT
-71.4m SEK
EBIT Growth EV/EBIT to Growth
SE
Ascelia Pharma AB
STO:ACE
Average EV/EBIT: 18.9
Negative Multiple: -7.1
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -193 857.3 N/A N/A
US
Abbvie Inc
NYSE:ABBV
23.5
29%
0.8
US
Amgen Inc
NASDAQ:AMGN
18.3
20%
0.9
US
Gilead Sciences Inc
NASDAQ:GILD
14.9
11%
1.4
US
E
Epizyme Inc
F:EPE
Negative Multiple: -560.8 N/A N/A
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
20
17%
1.2
AU
CSL Ltd
ASX:CSL
23
14%
1.6
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
13.5
11%
1.2
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -301 N/A N/A
US
S
Seagen Inc
F:SGT
Negative Multiple: -59.6 N/A N/A

EV/EBIT Forward Multiples

Forward EV/EBIT multiple is a version of the EV/EBIT ratio that uses forecasted EBIT for the EV/EBIT calculation. 1-Year, 2-Years, and 3-Years forwards use EBIT forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward
EV/EBIT
31.8
2-Years Forward
EV/EBIT
-18.2
3-Years Forward
EV/EBIT
11.1